Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer. Reply.

Bardia A, Mayer IA, Kalinsky K.

N Engl J Med. 2019 Jun 13;380(24):2382. doi: 10.1056/NEJMc1903943. No abstract available.

PMID:
31189049
2.

Current Landscape of Immunotherapy in Breast Cancer: A Review.

Adams S, Gatti-Mays ME, Kalinsky K, Korde LA, Sharon E, Amiri-Kordestani L, Bear H, McArthur HL, Frank E, Perlmutter J, Page DB, Vincent B, Hayes JF, Gulley JL, Litton JK, Hortobagyi GN, Chia S, Krop I, White J, Sparano J, Disis ML, Mittendorf EA.

JAMA Oncol. 2019 Apr 11. doi: 10.1001/jamaoncol.2018.7147. [Epub ahead of print]

PMID:
30973611
3.

Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer.

O'Shaughnessy J, Kaklamani V, Kalinsky K.

Future Oncol. 2019 May;15(14):1641-1653. doi: 10.2217/fon-2018-0936. Epub 2019 Mar 20.

4.

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.

Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K.

N Engl J Med. 2019 Feb 21;380(8):741-751. doi: 10.1056/NEJMoa1814213.

PMID:
30786188
5.

Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.

Boughey JC, Alvarado MD, Lancaster RB, Symmans WF, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Goodellas C, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ; I-SPY2 Investigators.

NPJ Breast Cancer. 2019 Jan 2;5:2. doi: 10.1038/s41523-018-0096-0. eCollection 2019.

6.

Lymph node involvement: Positive about the role of the recurrence score in estrogen-driven breast cancer?

Kalinsky K, O'Regan RM.

Cancer. 2019 Jan 15;125(2):177-180. doi: 10.1002/cncr.31814. Epub 2018 Nov 2. No abstract available.

PMID:
30387877
7.

Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.

Boughey JC, Alvarado MD, Lancaster RB, Fraser Symmans W, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ; and I-SPY 2 Investigators.

NPJ Breast Cancer. 2018 Aug 17;4:26. doi: 10.1038/s41523-018-0074-6. eCollection 2018. Review. Erratum in: NPJ Breast Cancer. 2019 Jan 2;5:2.

8.

Convolutional Neural Network Using a Breast MRI Tumor Dataset Can Predict Oncotype Dx Recurrence Score.

Ha R, Chang P, Mutasa S, Karcich J, Goodman S, Blum E, Kalinsky K, Liu MZ, Jambawalikar S.

J Magn Reson Imaging. 2019 Feb;49(2):518-524. doi: 10.1002/jmri.26244. Epub 2018 Aug 21.

PMID:
30129697
9.

Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial.

Kalinsky K, Sparano JA, Zhong X, Andreopoulou E, Taback B, Wiechmann L, Feldman SM, Ananthakrishnan P, Ahmad A, Cremers S, Sireci AN, Cross JR, Marks DK, Mundi P, Connolly E, Crew KD, Maurer MA, Hibshoosh H, Lee S, Hershman DL.

Clin Transl Oncol. 2018 Nov;20(11):1474-1483. doi: 10.1007/s12094-018-1888-2. Epub 2018 May 7.

PMID:
29736694
10.

Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).

Abraham J, Coleman R, Elias A, Holmes FA, Kalinsky K, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M, Vogel C; Breast Cancer Therapy Expert Group (BCTEG).

Breast Cancer Res Treat. 2018 Aug;171(1):11-20. doi: 10.1007/s10549-018-4783-1. Epub 2018 May 4. Review.

PMID:
29725889
11.

A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.

O'Shaughnessy J, DeMichele A, Ma CX, Richards P, Yardley DA, Wright GS, Kalinsky K, Steis R, Diab S, Kennealey G, Geschwindt R, Jiang W, Rugo HS.

Breast Cancer Res Treat. 2018 Aug;170(3):547-557. doi: 10.1007/s10549-018-4770-6. Epub 2018 Apr 19.

PMID:
29675680
12.

Concurrent use of capecitabine with radiation therapy and survival in breast cancer (BC) after neoadjuvant chemotherapy.

Liu YL, Chin C, Catanese B, Lee SM, Zhan S, Kalinsky K, Connolly EP.

Clin Transl Oncol. 2018 Oct;20(10):1280-1288. doi: 10.1007/s12094-018-1859-7. Epub 2018 Mar 28.

PMID:
29594944
13.

Bevacizumab in breast cancer: a targeted therapy still in search of a target population.

Marks DK, Kalinsky K.

Semin Oncol. 2017 Aug;44(4):286-287. doi: 10.1053/j.seminoncol.2017.10.011. Epub 2017 Oct 31. No abstract available.

PMID:
29526257
14.

Dynamic Diffuse Optical Tomography for Monitoring Neoadjuvant Chemotherapy in Patients with Breast Cancer.

Gunther JE, Lim EA, Kim HK, Flexman M, Altoé M, Campbell JA, Hibshoosh H, Crew KD, Kalinsky K, Hershman DL, Hielscher AH.

Radiology. 2018 Jun;287(3):778-786. doi: 10.1148/radiol.2018161041. Epub 2018 Feb 12.

15.

Obesity's impact on survival is independent of dose adjustments in neoadjuvant chemotherapy in women with breast cancer.

Liu YL, Connolly EP, Kalinsky K.

Breast Cancer Res Treat. 2018 Feb;168(1):285. doi: 10.1007/s10549-017-4590-0. Epub 2017 Nov 24. No abstract available.

PMID:
29177604
16.

Expanding the Criteria for Nipple-Sparing Mastectomy in Patients With Poor Prognostic Features.

Jadeja P, Ha R, Rohde C, Ascherman J, Grant R, Chin C, Connolly E, Kalinsky K, Feldman S, Taback B.

Clin Breast Cancer. 2018 Jun;18(3):229-233. doi: 10.1016/j.clbc.2017.08.010. Epub 2017 Aug 24.

PMID:
28967559
17.

Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population.

Liu YL, Saraf A, Catanese B, Lee SM, Zhang Y, Connolly EP, Kalinsky K.

Breast Cancer Res Treat. 2018 Jan;167(1):277-288. doi: 10.1007/s10549-017-4507-y. Epub 2017 Sep 25.

18.

Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.

Adelson K, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, Han G, Villalona-Calero M, Ma CX, Hershman D, Baar J, Klein P, Cigler T, Budd GT, Novik Y, Tan AR, Tannenbaum S, Goel A, Levine E, Shapiro CL, Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D.

NPJ Breast Cancer. 2016 Dec 14;2:16037. doi: 10.1038/npjbcancer.2016.37. eCollection 2016.

19.

Invasive Lobular Breast Carcinoma: Pleomorphic Versus Classical Subtype, Associations and Prognosis.

Liu YL, Choi C, Lee SM, Zhong X, Hibshoosh H, Kalinsky K, Connolly EP.

Clin Breast Cancer. 2018 Apr;18(2):114-120. doi: 10.1016/j.clbc.2017.06.006. Epub 2017 Jun 23.

PMID:
28720418
20.

Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan.

Gray JE, Heist RS, Starodub AN, Camidge DR, Kio EA, Masters GA, Purcell WT, Guarino MJ, Misleh J, Schneider CJ, Schneider BJ, Ocean A, Johnson T, Gandhi L, Kalinsky K, Scheff R, Messersmith WA, Govindan SV, Maliakal PP, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM.

Clin Cancer Res. 2017 Oct 1;23(19):5711-5719. doi: 10.1158/1078-0432.CCR-17-0933. Epub 2017 Jul 5.

21.

A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).

Kalinsky K, Lee S, Rubin KM, Lawrence DP, Iafrarte AJ, Borger DR, Margolin KA, Leitao MM Jr, Tarhini AA, Koon HB, Pecora AL, Jaslowski AJ, Cohen GI, Kuzel TM, Lao CD, Kirkwood JM.

Cancer. 2017 Jul 15;123(14):2688-2697. doi: 10.1002/cncr.30663. Epub 2017 Mar 23.

22.

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT.

J Clin Oncol. 2017 Jul 1;35(19):2141-2148. doi: 10.1200/JCO.2016.70.8297. Epub 2017 Mar 14.

23.

Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients.

Lim EA, Gunther JE, Kim HK, Flexman M, Hibshoosh H, Crew K, Taback B, Campbell J, Kalinsky K, Hielscher A, Hershman DL.

Breast Cancer Res Treat. 2017 Apr;162(3):533-540. doi: 10.1007/s10549-017-4150-7. Epub 2017 Feb 11.

PMID:
28190249
24.

Survivorship care plans and adherence to lifestyle recommendations among breast cancer survivors.

Greenlee H, Molmenti CL, Crew KD, Awad D, Kalinsky K, Brafman L, Fuentes D, Shi Z, Tsai WY, Neugut AI, Hershman DL.

J Cancer Surviv. 2016 Dec;10(6):956-963. Epub 2016 Apr 21.

PMID:
27100859
25.

Long-term Diet and Biomarker Changes after a Short-term Intervention among Hispanic Breast Cancer Survivors: The ¡Cocinar Para Su Salud! Randomized Controlled Trial.

Greenlee H, Ogden Gaffney A, Aycinena AC, Koch P, Contento I, Karmally W, Richardson JM, Shi Z, Lim E, Tsai WY, Santella RM, Blaner WS, Clugston RD, Cremers S, Pollak S, Sirosh I, Crew KD, Maurer M, Kalinsky K, Hershman DL.

Cancer Epidemiol Biomarkers Prev. 2016 Nov;25(11):1491-1502. Epub 2016 Jul 26.

26.

Monitoring Metastasis and Cachexia in a Patient with Breast Cancer: A Case Study.

Consul N, Guo X, Coker C, Lopez-Pintado S, Hibshoosh H, Zhao B, Kalinsky K, Acharyya S.

Clin Med Insights Oncol. 2016 Sep 11;10:83-94. doi: 10.4137/CMO.S40479. eCollection 2016.

27.

An analysis of the relationship between metastases and cachexia in lung cancer patients.

Shiono M, Huang K, Downey RJ, Consul N, Villanueva N, Beck K, Fenn K, Dietz D, Yamaguchi T, Kato S, Divgi C, Kalinsky K, Wei Y, Zhang Y, Borczuk AC, Inoue A, Halmos B, Acharyya S.

Cancer Med. 2016 Sep;5(9):2641-8. doi: 10.1002/cam4.841. Epub 2016 Aug 3.

28.

Proteomic modulation in breast tumors after metformin exposure: results from a "window of opportunity" trial.

Kalinsky K, Zheng T, Hibshoosh H, Du X, Mundi P, Yang J, Refice S, Feldman SM, Taback B, Connolly E, Crew KD, Maurer MA, Hershman DL.

Clin Transl Oncol. 2017 Feb;19(2):180-188. doi: 10.1007/s12094-016-1521-1. Epub 2016 Jun 15.

PMID:
27305912
29.

AKT in cancer: new molecular insights and advances in drug development.

Mundi PS, Sachdev J, McCourt C, Kalinsky K.

Br J Clin Pharmacol. 2016 Oct;82(4):943-56. doi: 10.1111/bcp.13021. Epub 2016 Jun 27. Review.

30.

Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy.

Liu YL, Saraf A, Lee SM, Zhong X, Hibshoosh H, Kalinsky K, Connolly EP.

Breast Cancer Res Treat. 2016 Jun;157(3):555-64. doi: 10.1007/s10549-016-3837-5. Epub 2016 May 25.

31.

Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer.

Greenlee H, Crew KD, Capodice J, Awad D, Buono D, Shi Z, Jeffres A, Wyse S, Whitman W, Trivedi MS, Kalinsky K, Hershman DL.

Breast Cancer Res Treat. 2016 Apr;156(3):453-464. doi: 10.1007/s10549-016-3759-2. Epub 2016 Mar 25.

32.

Identifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics Technology.

Chen EI, Crew KD, Trivedi M, Awad D, Maurer M, Kalinsky K, Koller A, Patel P, Kim Kim J, Hershman DL.

PLoS One. 2015 Dec 28;10(12):e0145816. doi: 10.1371/journal.pone.0145816. eCollection 2015.

33.

Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy.

Zhang C, Wang S, Israel HP, Yan SX, Horowitz DP, Crockford S, Gidea-Addeo D, Clifford Chao KS, Kalinsky K, Connolly EP.

Springerplus. 2015 Jul 30;4:386. doi: 10.1186/s40064-015-1116-2. eCollection 2015.

34.

Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers.

Rodriguez-Barrueco R, Yu J, Saucedo-Cuevas LP, Olivan M, Llobet-Navas D, Putcha P, Castro V, Murga-Penas EM, Collazo-Lorduy A, Castillo-Martin M, Alvarez M, Cordon-Cardo C, Kalinsky K, Maurer M, Califano A, Silva JM.

Genes Dev. 2015 Aug 1;29(15):1631-48. doi: 10.1101/gad.262642.115. Epub 2015 Jul 30.

35.

¡Cocinar Para Su Salud!: Randomized Controlled Trial of a Culturally Based Dietary Intervention among Hispanic Breast Cancer Survivors.

Greenlee H, Gaffney AO, Aycinena AC, Koch P, Contento I, Karmally W, Richardson JM, Lim E, Tsai WY, Crew K, Maurer M, Kalinsky K, Hershman DL.

J Acad Nutr Diet. 2015 May;115(5 Suppl):S42-S56.e3. doi: 10.1016/j.jand.2015.02.027.

36.

Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.

Reimers LL, Sivasubramanian PS, Hershman D, Terry MB, Greenlee H, Campbell J, Kalinsky K, Maurer M, Jayasena R, Sandoval R, Alvarez M, Crew KD.

Breast J. 2015 Jul-Aug;21(4):377-86. doi: 10.1111/tbj.12418. Epub 2015 Apr 16.

37.

Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients.

Kalinsky K, Mayer JA, Xu X, Pham T, Wong KL, Villarin E, Pircher TJ, Brown M, Maurer MA, Bischoff FZ.

Clin Transl Oncol. 2015 Jul;17(7):539-46. doi: 10.1007/s12094-015-1275-1. Epub 2015 Jan 23.

38.

¡Cocinar Para Su Salud!: Randomized Controlled Trial of a Culturally Based Dietary Intervention among Hispanic Breast Cancer Survivors.

Greenlee H, Gaffney AO, Aycinena AC, Koch P, Contento I, Karmally W, Richardson JM, Lim E, Tsai WY, Crew K, Maurer M, Kalinsky K, Hershman DL.

J Acad Nutr Diet. 2015 May;115(5):709-723.e3. doi: 10.1016/j.jand.2014.11.002. Epub 2015 Jan 8.

39.

Safety, Feasibility, and Biomarker Effects of High-Dose Vitamin D Supplementation Among Women at High Risk for Breast Cancer.

Crew KD, Xiao T, Thomas PS, Terry MB, Maurer M, Kalinsky K, Feldman S, Brafman L, Refice SR, Hershman DL.

Int J Food Sci Nutr Diet. 2015;2015(Suppl 1):1-16. doi: 10.19070/2326-3350-SI01001. Epub 2015 Feb 23.

40.

Concomitant angiosarcoma and lymphoproliferative disorder in solid organ transplant recipients.

Baer LN, Savage DG, Hibshoosh HH, Kalinsky K.

Clin Sarcoma Res. 2014 Oct 31;4(1):15. doi: 10.1186/2045-3329-4-15. eCollection 2014.

41.

Increased expression of tumor proliferation genes in Hispanic women with early-stage breast cancer.

Kalinsky K, Lim EA, Andreopoulou E, Desai AM, Jin Z, Tu Y, Hibshoosh H, Wang A, Greenlee H, Crew KD, Maurer M, Sparano JA, Hershman DL.

Cancer Invest. 2014 Nov;32(9):439-44. doi: 10.3109/07357907.2014.958232. Epub 2014 Sep 25.

42.

A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer.

Tu Y, Hershman DL, Bhalla K, Fiskus W, Pellegrino CM, Andreopoulou E, Makower D, Kalinsky K, Fehn K, Fineberg S, Negassa A, Montgomery LL, Wiechmann LS, Alpaugh RK, Huang M, Sparano JA.

Breast Cancer Res Treat. 2014 Jul;146(1):145-52. doi: 10.1007/s10549-014-3008-5. Epub 2014 Jun 6.

PMID:
24903226
43.

Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer.

Kalinsky K, Crew KD, Refice S, Xiao T, Wang A, Feldman SM, Taback B, Ahmad A, Cremers S, Hibshoosh H, Maurer M, Hershman DL.

Cancer Invest. 2014 May;32(4):150-7. doi: 10.3109/07357907.2014.889706. Epub 2014 Mar 7.

44.

Room for improvement in breast cancer clinical trial design: taking advantage of the preoperative setting.

Kalinsky K, Hershman DL.

J Comp Eff Res. 2013 Jul;2(4):393-403. doi: 10.2217/cer.13.35.

45.

Optical biomarkers for breast cancer derived from dynamic diffuse optical tomography.

Flexman ML, Kim HK, Gunther JE, Lim EA, Alvarez MC, Desperito E, Kalinsky K, Hershman DL, Hielscher AH.

J Biomed Opt. 2013 Sep;18(9):096012. doi: 10.1117/1.JBO.18.9.096012.

PMID:
24048367
46.

Randomized controlled trial of a clinic-based survivorship intervention following adjuvant therapy in breast cancer survivors.

Hershman DL, Greenlee H, Awad D, Kalinsky K, Maurer M, Kranwinkel G, Brafman L, Jayasena R, Tsai WY, Neugut AI, Crew KD.

Breast Cancer Res Treat. 2013 Apr;138(3):795-806. doi: 10.1007/s10549-013-2486-1. Epub 2013 Mar 31.

PMID:
23542954
47.

Use of a urine anastrozole assay to determine treatment discontinuation among women with hormone-sensitive breast cancer: a pilot study.

Clarke Hillyer G, Neugut AI, Crew KD, Kalinsky K, Maurer MA, Rotsides DZ, Danaceau J, Hershman DL.

J Oncol Pract. 2012 Sep;8(5):e100-4. doi: 10.1200/JOP.2011.000487. Epub 2012 Jun 26.

48.

Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer.

Greenlee H, Crew KD, Shao T, Kranwinkel G, Kalinsky K, Maurer M, Brafman L, Insel B, Tsai WY, Hershman DL.

Support Care Cancer. 2013 Apr;21(4):1077-87. doi: 10.1007/s00520-012-1628-z. Epub 2012 Nov 1.

49.

Influence of health insurance, hospital factors and physician volume on receipt of immediate post-mastectomy reconstruction in women with invasive and non-invasive breast cancer.

Hershman DL, Richards CA, Kalinsky K, Wilde ET, Lu YS, Ascherman JA, Neugut AI, Wright JD.

Breast Cancer Res Treat. 2012 Nov;136(2):535-45. doi: 10.1007/s10549-012-2273-4. Epub 2012 Sep 29.

50.

Cracking open window of opportunity trials.

Kalinsky K, Hershman DL.

J Clin Oncol. 2012 Jul 20;30(21):2573-5. doi: 10.1200/JCO.2012.42.3293. Epub 2012 May 7. No abstract available.

PMID:
22565006

Supplemental Content

Loading ...
Support Center